Please login to the form below

Not currently logged in
Email:
Password:

Chiesi targets patient adherence via mobile app

Initiative will see asthma and COPD patients receive device training support

ChiesiChiesi Limited, the UK affiliate of Italian healthcare company Chiesi Farmaceutici, has launched a new mobile app for adult patients with asthma or chronic obstructive pulmonary disease (COPD) to support with patient adherence and device technique.

The app, which will be used by healthcare professionals, is specifically catered to those who have been prescribed Chiesi’s Fostair (beclometasone/formoterol) pressurised metered-dose inhaler (pMDI) or dry powder inhaler Fostair NEXThaler.

According to the group, inefficient inhalation technique is a common problem as patients tend to forget to how to use their inhalers appropriately and introducing new errors with time.

Inhaler misuse has been associated with increased risk of hospitalisation, courses of oral steroids and poor disease control.

Patients using Chiesi’s app will be able to review their inhaler technique and can share this during their consultations with their HCPs.

The new app also offers dose reminders and a dose history review to help recognise patterns.

Tom Delahoyde, managing director of Chiesi LTD, said: “Our aim is to help HCPs to better support patients in achieving the desired outcome from their Fostair treatment.

“With this in mind, we have designed an app which aims to support HCPs with patients inhaler technique training.”

The app is available on both Android and Apple operating systems.

Article by
Gemma Jones

18th June 2018

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...